Jagsonpal Pharmaceuticals Limited Q4 FY25 earnings call summary

Earnings call of 7 May 2025, summarised by AI from the filing.

Jagsonpal FY25 revenue ₹2,687 million (+28.8%) and PAT ₹554 million; guides 15%+ revenue growth in FY26.

Key takeaways

1. FY26 guidance 15% plus revenue growth expected in current year, with higher operating profit growth and improved margins.
2. Working capital Reduced to 13 days or 3.5% of sales; most low-hanging fruits now in place.

Original filing on BSE

Jagsonpal Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹82.2 cr (+8% year on year), EBITDA ₹17.2 cr (+33% year on year), PAT ₹13.2 cr (+20% year on year), EBITDA margin 21.0% (+386 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹64.2 cr (+9% year on year), EBITDA ₹11.2 cr (+40% year on year), PAT ₹8.8 cr (+25% year on year), EBITDA margin 17.4% (+382 bps). Score 38 of 100, Below trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin rose 382 bps year on year. Other income 27% of PBT. Revenue fell 12% from last quarter. Share price after the results: +2.6% in 30 days (Nifty 500: +0.6%).
• Q3 FY26: Revenue ₹73.0 cr (−1% year on year), EBITDA ₹16.3 cr (+2% year on year), PAT ₹11.0 cr (+4% year on year), EBITDA margin 22.3% (+68 bps). Score 41 of 100, In line with trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin rose 68 bps year on year. Share price after the results: +5.4% in 30 days (Nifty 500: +2.5%).
• Q2 FY26: Revenue ₹74.0 cr (−1% year on year), EBITDA ₹16.0 cr (+7% year on year), PAT ₹13.0 cr (+18% year on year), EBITDA margin 21.6% (+162 bps). Score 41 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 162 bps year on year. Share price after the results: −4.7% in 30 days (Nifty 500: −0.4%).
• Q1 FY26: Revenue ₹76.0 cr (+25% year on year), EBITDA ₹13.0 cr (+30% year on year), PAT ₹11.0 cr (+120% year on year), EBITDA margin 17.1% (+71 bps). Score 65 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was below it. EBITDA margin rose 71 bps year on year. Share price after the results: −9.4% in 30 days (Nifty 500: +0.2%).
• Q4 FY25: Revenue ₹59.0 cr (+37% year on year), EBITDA ₹8.0 cr (+167% year on year), PAT ₹7.0 cr (+75% year on year), EBITDA margin 13.6% (+658 bps). Score 57 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was in line with it. EBITDA margin rose 658 bps year on year. Other income 33% of PBT. Revenue fell 20% from last quarter. Share price after the results: −2.8% in 30 days (Nifty 500: +4.5%).
• Q3 FY25: Revenue ₹74.0 cr (+57% year on year), EBITDA ₹16.0 cr (+300% year on year), PAT ₹32.0 cr (+220% year on year), EBITDA margin 21.6% (+1,000 bps). Score 100 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone.
• Q2 FY25: Revenue ₹75.0 cr, EBITDA ₹15.0 cr, PAT ₹11.0 cr, EBITDA margin 20.0%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Jagsonpal Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (30 Jul 2026), Results deck (29 Jul 2026), Results press release (29 Jul 2026)
• Q4 FY26: Earnings call (28 Apr 2026), Results deck (27 Apr 2026), Results press release (27 Apr 2026)
• Q3 FY26: Earnings call (22 Jan 2026), Results deck (21 Jan 2026)
• Q2 FY26: Earnings call (4 Nov 2025), Results deck (3 Nov 2025)
• Q1 FY26: Earnings call (28 Jul 2025), Results deck (26 Jul 2025), Results deck (26 Jul 2025), Results press release (26 Jul 2025), Results press release (26 Jul 2025)
• Q4 FY25: Earnings call (7 May 2025), Results deck (6 May 2025)